{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-26-031419","form_type":"8-K","ticker":"MBRX","cik":"0001659617","company_name":"Moleculin Biotech, Inc.","filed_at":"2026-09-29T12:45:26+00:00","discovered_at":"2026-09-29T12:50:00.319533+00:00","generated_at":"2026-10-12T13:43:45.973347+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Moleculin Biotech completes Part A enrollment in Phase 2/3 MIRACLE trial with 89 R/R AML subjects","bullets":["Part A of the pivotal Phase 2/3 MIRACLE trial closed enrollment with 89 subjects enrolled and one additional subject in screening.","Moleculin remains on track for a comprehensive Part A data readout in Q1 2027.","The full Part A population is expected to be approximately 50/50 between 1L 7+3 and venetoclax-based regimens, versus a 70/30 split in the first 45 subjects.","CEO Walter Klemp said the Q1 2027 readout will be deeper in data than the first interim n45 readout.","The company continues to see no cardiotoxicity in blinded MIRACLE data; AnnAraC combines Annamycin with cytarabine."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-26-031419","json":"https://secwatch.observer/filing/0001437749-26-031419.json","markdown":"https://secwatch.observer/filing/0001437749-26-031419.md","text":"https://secwatch.observer/filing/0001437749-26-031419.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1659617/000143774926031419/0001437749-26-031419-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1659617/000143774926031419/mbrx20260928_8k.htm"},"model":{"generated_by":"deepseek-v4.1-flash:cloud@v2","generated_at":"2026-10-12T13:43:45.973347+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}